Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

133,426 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
SCH 2047069, a novel oral kinesin spindle protein inhibitor, shows single-agent antitumor activity and enhances the efficacy of chemotherapeutics.
Basso AD, Liu M, Dai C, Gray K, Nale L, Tevar S, Lee S, Liang L, Ponery A, Yaremko B, Smith E, Tang H, Sheth PR, Siddiqui MA, Hicklin DJ, Kirschmeier P. Basso AD, et al. Among authors: lee s. Mol Cancer Ther. 2010 Nov;9(11):2993-3002. doi: 10.1158/1535-7163.MCT-10-0548. Epub 2010 Oct 26. Mol Cancer Ther. 2010. PMID: 20978164
SCH 1473759, a novel Aurora inhibitor, demonstrates enhanced anti-tumor activity in combination with taxanes and KSP inhibitors.
Basso AD, Liu M, Gray K, Tevar S, Lee S, Liang L, Ponery A, Smith EB, Monsma FJ Jr, Yu T, Zhang Y, Kerekes AD, Esposite S, Xiao Y, Tagat JR, Hicklin DJ, Kirschmeier P. Basso AD, et al. Among authors: lee s. Cancer Chemother Pharmacol. 2011 Oct;68(4):923-33. doi: 10.1007/s00280-011-1568-1. Epub 2011 Feb 5. Cancer Chemother Pharmacol. 2011. PMID: 21298383
Discovery of orally bioavailable imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors.
Belanger DB, Williams MJ, Curran PJ, Mandal AK, Meng Z, Rainka MP, Yu T, Shih NY, Siddiqui MA, Liu M, Tevar S, Lee S, Liang L, Gray K, Yaremko B, Jones J, Smith EB, Prelusky DB, Basso AD. Belanger DB, et al. Among authors: lee s. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6739-43. doi: 10.1016/j.bmcl.2010.08.140. Epub 2010 Sep 18. Bioorg Med Chem Lett. 2010. PMID: 20855207
Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice.
Liu M, Bryant MS, Chen J, Lee S, Yaremko B, Lipari P, Malkowski M, Ferrari E, Nielsen L, Prioli N, Dell J, Sinha D, Syed J, Korfmacher WA, Nomeir AA, Lin CC, Wang L, Taveras AG, Doll RJ, Njoroge FG, Mallams AK, Remiszewski S, Catino JJ, Girijavallabhan VM, Bishop WR, et al. Liu M, et al. Among authors: lee s. Cancer Res. 1998 Nov 1;58(21):4947-56. Cancer Res. 1998. PMID: 9810004
Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice.
Liu M, Bryant MS, Chen J, Lee S, Yaremko B, Li Z, Dell J, Lipari P, Malkowski M, Prioli N, Rossman RR, Korfmacher WA, Nomeir AA, Lin CC, Mallams AK, Doll RJ, Catino JJ, Girijavallabhan VM, Kirschmeier P, Bishop WR. Liu M, et al. Among authors: lee s. Cancer Chemother Pharmacol. 1999;43(1):50-8. doi: 10.1007/s002800050862. Cancer Chemother Pharmacol. 1999. PMID: 9923541
Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening.
Guzi TJ, Paruch K, Dwyer MP, Labroli M, Shanahan F, Davis N, Taricani L, Wiswell D, Seghezzi W, Penaflor E, Bhagwat B, Wang W, Gu D, Hsieh Y, Lee S, Liu M, Parry D. Guzi TJ, et al. Among authors: lee s. Mol Cancer Ther. 2011 Apr;10(4):591-602. doi: 10.1158/1535-7163.MCT-10-0928. Epub 2011 Feb 14. Mol Cancer Ther. 2011. PMID: 21321066
Discovery of a Potent, Injectable Inhibitor of Aurora Kinases Based on the Imidazo-[1,2-a]-Pyrazine Core.
Yu T, Tagat JR, Kerekes AD, Doll RJ, Zhang Y, Xiao Y, Esposite S, Belanger DB, Curran PJ, Mandal AK, Siddiqui MA, Shih NY, Basso AD, Liu M, Gray K, Tevar S, Jones J, Lee S, Liang L, Ponery S, Smith EB, Hruza A, Voigt J, Ramanathan L, Prosise W, Hu M. Yu T, et al. Among authors: lee s. ACS Med Chem Lett. 2010 Jun 7;1(5):214-8. doi: 10.1021/ml100063w. eCollection 2010 Aug 12. ACS Med Chem Lett. 2010. PMID: 24900197 Free PMC article.
Structure-activity relationship of 3-substituted N-(pyridinylacetyl)-4- (8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene )- piperidine inhibitors of farnesyl-protein transferase: design and synthesis of in vivo active antitumor compounds.
Njoroge FG, Vibulbhan B, Rane DF, Bishop WR, Petrin J, Patton R, Bryant MS, Chen KJ, Nomeir AA, Lin CC, Liu M, King I, Chen J, Lee S, Yaremko B, Dell J, Lipari P, Malkowski M, Li Z, Catino J, Doll RJ, Girijavallabhan V, Ganguly AK. Njoroge FG, et al. Among authors: lee s. J Med Chem. 1997 Dec 19;40(26):4290-301. doi: 10.1021/jm970464g. J Med Chem. 1997. PMID: 9435898
Inhibitors of farnesyl protein transferase. 4-Amido, 4-carbamoyl, and 4-carboxamido derivatives of 1-(8-chloro-6,11-dihydro-5H-benzo[5,6]- cyclohepta[1,2-b]pyridin-11-yl)piperazine and 1-(3-bromo-8-chloro-6,11- dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)piperazine.
Mallams AK, Rossman RR, Doll RJ, Girijavallabhan VM, Ganguly AK, Petrin J, Wang L, Patton R, Bishop WR, Carr DM, Kirschmeier P, Catino JJ, Bryant MS, Chen KJ, Korfmacher WA, Nardo C, Wang S, Nomeir AA, Lin CC, Li Z, Chen J, Lee S, Dell J, Lipari P, Liu M, et al. Mallams AK, et al. Among authors: lee s. J Med Chem. 1998 Mar 12;41(6):877-93. doi: 10.1021/jm970462w. J Med Chem. 1998. PMID: 9526562
133,426 results
You have reached the last available page of results. Please see the User Guide for more information.